Asthma medication options
Pro Research Analysisby 
Searched over 200M research papers
Inhaled Corticosteroids (ICS) and Long-Acting Beta-Agonists (LABA) in Asthma Medication
Inhaled corticosteroids (ICS) such as fluticasone and budesonide are foundational treatments for asthma, helping to control inflammation and prevent symptoms. Long-acting beta-agonists (LABA) like formoterol and salmeterol are often added to ICS for better symptom control. Studies show that fluticasone and formoterol may offer greater improvements in lung function and symptom control compared to budesonide and salmeterol, respectively. Combination inhalers (ICS/LABA) are generally more effective than using either medication alone, with similar tolerability profiles. Notably, the risk of growth retardation is lower with fluticasone than with budesonide, and with budesonide/formoterol compared to budesonide alone .
Single Maintenance and Reliever Therapy (SMART) and As-Needed Asthma Treatments
For mild-to-moderate asthma, single maintenance and reliever therapy (SMART)—using a combination ICS/LABA inhaler both for daily maintenance and as-needed relief—has been shown to reduce the risk of exacerbations more effectively than other as-needed therapies. In moderate-to-severe asthma, both low- to medium-dose SMART and high-dose ICS/LABA with as-needed short-acting beta-agonists are effective, but SMART is often ranked as the top option. These regimens are well tolerated and improve both lung function and overall disease control .
Add-On and Alternative Asthma Medication Options
When asthma remains uncontrolled with ICS/LABA therapy, additional medications can be considered. Long-acting muscarinic antagonists (LAMA), such as tiotropium, can further improve lung function and reduce exacerbations, especially in patients with more severe or low-T2 asthma phenotypes. Single-inhaler triple therapy (ICS/LABA/LAMA) is a newer option that can enhance symptom control, lung function, and possibly reduce exacerbations, while also improving treatment adherence 1073.
Other add-on options include leukotriene receptor antagonists, sustained-release theophylline, and allergen immunotherapy. In resource-limited settings, oral theophylline and oral salbutamol may be used as more affordable alternatives to inhaled medications, though they may be less effective and require careful monitoring 932.
Biologic Therapies for Severe or Refractory Asthma
For patients with severe asthma that does not respond to standard therapies, biologic medications are now available. These include monoclonal antibodies targeting immunoglobulin E (IgE), interleukin-5 (IL-5), the IL-5 receptor, and the IL-4/IL-13 receptor. Examples are omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. These biologics can improve asthma control, reduce exacerbations, and decrease the need for oral steroids, especially in patients with specific asthma phenotypes such as allergic or eosinophilic asthma 573.
Other and Emerging Asthma Medication Options
Additional therapies under investigation include mediator antagonists, cytokine inhibitors, and new anti-inflammatory agents like phosphodiesterase-4 inhibitors. Bronchial thermoplasty, a non-drug procedure, is also an option for some patients with severe, uncontrolled asthma 637.
Conclusion
Asthma medication options range from inhaled corticosteroids and long-acting beta-agonists, often used in combination, to add-on therapies like LAMA and leukotriene receptor antagonists. For severe or refractory cases, biologic therapies and bronchial thermoplasty offer new hope. Treatment should be tailored to the severity and phenotype of asthma, with consideration for patient-specific factors and resource availability 1345+2 MORE.
Sources and full results
Most relevant research papers on this topic